Neutrophils’ dual role in cancer: from tumor progression to immunotherapeutic potential
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112788 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Gujie Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Neutrophils, Tumor Microenvironment, Immunotherapy, Neoplasms. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 117 Literaturangaben. Gefördert von: Fudan University, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
The tumor microenvironment (TME) is intricately associated with cancer progression, characterized by dynamic interactions among various cellular and molecular components that significantly impact the carcinogenic process. Notably, neutrophils play a crucial dual role in regulating this complex environment. These cells oscillate between promoting and inhibiting tumor activity, responding to a multitude of cytokines, chemokines, and tumor-derived factors. This response modulates immune reactions and affects the proliferation, metastasis, and angiogenesis of cancer cells. A significant aspect of their influence is their interaction with the endoplasmic reticulum (ER) stress responses in cancer cells, markedly altering tumor immunodynamics by modulating the phenotypic plasticity and functionality of neutrophils. Furthermore, neutrophil extracellular traps (NETs) exert a pivotal influence in the progression of malignancies by enhancing inflammation, metastasis, immune suppression, and thrombosis, thereby exacerbating the disease. In the realm of immunotherapy, checkpoint inhibitors targeting PD-L1/PD-1 and CTLA-4 among others have underscored the significant role of neutrophils in enhancing therapeutic responses. Recent research has highlighted the potential of using neutrophils for targeted drug delivery through nanoparticle systems, which precisely control drug release and significantly enhance antitumor efficacy. This review thoroughly examines the diverse functions of neutrophils in cancer treatment, emphasizing their potential in regulating immune therapy responses and as drug delivery carriers, offering innovative perspectives and profound implications for the development of targeted diagnostic and therapeutic strategies in oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Radiation Oncology, Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.
- Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, China.
- Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Center, Shanghai, China.
- Regenerative Medicine Institute, School of Medicine, National University of Ireland (NUI), Galway, Ireland. Electronic address: L.Cheng1@nuigalway.ie.
- Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address: huang.yiwei@zs-hospital.sh.cn.
Förderung
- Fudan University
- China Postdoctoral Science Foundation
Zitieren
APA
Wu, G., Pan, B., Shi, H., Yi, Y., Zheng, X., Ma, H., Zhao, M., Zhang, Z., Cheng, L., Huang, Y., & Guo, W. (2024). Neutrophils’ dual role in cancer: from tumor progression to immunotherapeutic potential. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112788
Vancouver
Wu G, Pan B, Shi H, Yi Y, Zheng X, Ma H, et al. Neutrophils’ dual role in cancer: from tumor progression to immunotherapeutic potential. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112788
BibTeX
@article{Wu2024,
author = {Wu, Gujie and Pan, Binyang and Shi, Haochun and Yi, Yanjun and Zheng, Xiaobin and Ma, Huiyun and Zhao, Mengnan and Zhang, Zhenshan and Cheng, Lin and Huang, Yiwei and Guo, Weigang},
title = {Neutrophils’ dual role in cancer: from tumor progression to immunotherapeutic potential},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112788}
}
EUVIMED